Review covers how plant and body-made cannabinoids affect brain diseases
A review of phytocannabinoids and endocannabinoids found diverse pharmacological activities relevant to CNS diseases including epilepsy, pain, neurodegeneration, and psychiatric disorders, though clinical evidence varies widely by condition.
Quick Facts
What This Study Found
Both plant-derived (phyto) and endogenous cannabinoids show pharmacological activities relevant to multiple CNS conditions. Evidence quality ranges from well-supported (epilepsy) to preliminary (neurodegeneration, psychiatric disorders).
Key Numbers
Review covers phytocannabinoids (THC, CBD, others) and endocannabinoids (anandamide, 2-AG) across multiple CNS disease categories.
How They Did This
Literature review using keyword searches across databases focusing on cannabinoid pharmacology and CNS disease applications. Covers both phytocannabinoids and endocannabinoids.
Why This Research Matters
The endocannabinoid system is active throughout the brain and involved in nearly every neurological function. Understanding how both external and internal cannabinoids modulate brain disease opens numerous therapeutic avenues.
The Bigger Picture
The diversity of CNS conditions potentially influenced by cannabinoid signaling reflects the central role of the endocannabinoid system in brain function. Translating this broad pharmacology into targeted therapies remains the key challenge.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Covers a very broad topic with variable evidence depth. Much of the evidence is preclinical. Does not provide quantitative evidence synthesis.
Questions This Raises
- ?Which CNS conditions have the strongest clinical evidence for cannabinoid-based therapies beyond epilepsy?
- ?How can the broad pharmacology of cannabinoids be harnessed for specific conditions without off-target effects?
Trust & Context
- Key Stat:
- Cannabinoid pharmacology spans epilepsy, pain, neurodegeneration, and psychiatric disorders
- Evidence Grade:
- Broad narrative review. Useful overview but limited by scope breadth and lack of systematic evidence grading.
- Study Age:
- Published 2023.
- Original Title:
- The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review.
- Published In:
- Journal of traditional and complementary medicine, 13(1), 30-38 (2023)
- Authors:
- Zhang, Shan-Shan, Zhang, Niu-Niu, Guo, Tian-Tian, Sheen, Lee-Yan, Ho, Chi-Tang, Bai, Nai-Sheng
- Database ID:
- RTHC-05052
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids treat brain diseases?
The evidence varies by condition. CBD for certain epilepsy syndromes has strong clinical support. For other conditions like neurodegeneration and psychiatric disorders, evidence is mostly preclinical or preliminary clinical. The endocannabinoid system is deeply involved in brain function, providing biological rationale for further research.
What is the difference between phytocannabinoids and endocannabinoids?
Phytocannabinoids (like THC and CBD) come from the cannabis plant. Endocannabinoids (like anandamide and 2-AG) are produced naturally by the human body. Both interact with cannabinoid receptors and other targets in the brain, but their effects, duration, and potency differ.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05052APA
Zhang, Shan-Shan; Zhang, Niu-Niu; Guo, Tian-Tian; Sheen, Lee-Yan; Ho, Chi-Tang; Bai, Nai-Sheng. (2023). The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review.. Journal of traditional and complementary medicine, 13(1), 30-38. https://doi.org/10.1016/j.jtcme.2022.10.004
MLA
Zhang, Shan-Shan, et al. "The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review.." Journal of traditional and complementary medicine, 2023. https://doi.org/10.1016/j.jtcme.2022.10.004
RethinkTHC
RethinkTHC Research Database. "The impact of phyto- and endo-cannabinoids on central nervou..." RTHC-05052. Retrieved from https://rethinkthc.com/research/zhang-2023-the-impact-of-phyto
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.